AveXis appoints chief compliance officer

By 2016-07-11T09:15:00

AveXis, a clinical-stage gene therapy company developing treatments for patients suffering from rare and life-threatening neurological genetic diseases, has appointed Michael Johannesen to the executive management team as general counsel and chief compliance officer. He will report to President and CEO Sean Nolan.

lock iconTHIS IS MEMBERS-ONLY CONTENT. To continue reading, choose one of the options below.

Become a Member

News and analysis for the well-informed compliance or audit exec. Select an option and click continue.

Annual Membership $499 Value offer

Full price one year membership with auto-renewal.

Membership $599

One-year only, no auto-renewal.

Access CW Newsletters and CPE webcasts. REGISTER FOR LIMITED FREE ACCESS
Already a Compliance Week member?